NXTC - Pyxis Oncology: Data Arriving Later Than Expected But May Be Worth The Wait
2024-03-28 00:10:26 ET
Summary
- Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types.
- Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively.
- PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26.
...
Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait